ArticleMicrobial biotechnology2022
Rapid preparation and antimicrobial activity of polyurea coatings with RE-Doped nano-ZnO.
Article in Microbial biotechnology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 22 citations in OpenAlex.
- Article
- Combatting biofilms in potable water systems: A comprehensive overview to ensuring industrial water safety.Environmental microbiology reports · 2023Review
- Electrospun nanofibers for medical face mask with protection capabilities against viruses: State of the art and perspective for industrial scale-up.Applied materials today · 2023Review
- In Vitro Antimicrobial and Anticancer Peculiarities of Ytterbium and Cerium Co-Doped Zinc Oxide Nanoparticles.Biology · 2022Article
- A Comparative Study on the Self-Healing Characterizations and Formulation Optimization of Polyurea Coating.Polymers · 2022Article
- Mini-Review of Self-Healing Mechanism and Formulation Optimization of Polyurea Coating.Polymers · 2022Review
- Rapid preparation and antimicrobial activity of polyurea coatings with RE-Doped nano-ZnO.Microbial biotechnology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 2 countries.
Funding
Abstract
The recent COVID-19 virus has led to a rising interest in antimicrobial and antiviral coatings for frequently touched surfaces in public and healthcare settings. Such coatings may have the ability to kill a variety of microorganisms and bio-structures and reduce the risk of virus transmission. This paper proposes an extremely rapid method to introduce rare-earth doping nano-ZnO in polyamines for the preparation of the anti-microbial polyurea coatings. The nano-ZnO is prepared by wet chemical method, and the RE-doped nano-ZnO was obtained by mixing nano ZnO and RE-dopants with an appropriate amount of nitric acid. This rapidly fabricated polyurea coating can effectively reduce bacteria from enriching on the surface. Comparing with pure nano-ZnO group, all the polyurea coatings with four different rare-earth elements (La, Ce, Pr and Gd) doped nano-ZnO. The La-doped nano-ZnO formula group indicates the highest bactericidal rate over 85% to Escherichia coli (E. coli) and Pseudomonas aeruginosa (Pseudomonas). Followed by Ce/ZnO, the bactericidal rate may still remain as high as 83% at room temperature after 25-min UV-exposure. It is believed that the RE-doping process may greatly improve the photocatalytic response to UV light as well as environmental temperature due to its thermal catalytic enhancement. Through the surface characterizations and bioassays, the coatings have a durably high bactericidal rate even after repeated usage. As polyurea coating itself has high mechanical strength and adhesive force with most substrate materials without peel-off found, this rapid preparation method will also provide good prospects in practical applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.